On Tuesday, Amneal Pharmaceuticals Inc (NASDAQ: AMRX) was -1.90% drop from the session before settling in for the closing price of $8.41. A 52-week range for AMRX has been $3.96 – $8.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 7.85%. When this article was written, the company’s average yearly earnings per share was at -6.36%. With a float of $119.85 million, this company’s outstanding shares have now reached $306.56 million.
Considering the fact that the conglomerate employs 7850 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 35.04%, operating margin of 6.72%, and the pretax margin is -4.45%.
Amneal Pharmaceuticals Inc (AMRX) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Amneal Pharmaceuticals Inc stocks. The insider ownership of Amneal Pharmaceuticals Inc is 61.28%, while institutional ownership is 39.51%. The most recent insider transaction that took place on Aug 15 ’24, was worth 315,766. In this transaction Executive Vice President of this company sold 40,225 shares at a rate of $7.85, taking the stock ownership to the 256,670 shares. Before that another transaction happened on Aug 14 ’24, when Company’s Executive Vice President sold 22,486 for $7.81, making the entire transaction worth $175,616. This insider now owns 296,895 shares in total.
Amneal Pharmaceuticals Inc (AMRX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -6.36% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 3.00% during the next five years compared to -23.74% drop over the previous five years of trading.
Amneal Pharmaceuticals Inc (NASDAQ: AMRX) Trading Performance Indicators
You can see what Amneal Pharmaceuticals Inc (AMRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.98. Likewise, its price to free cash flow for the trailing twelve months is 56.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.62, a number that is poised to hit 0.13 in the next quarter and is forecasted to reach 0.70 in one year’s time.
Technical Analysis of Amneal Pharmaceuticals Inc (AMRX)
Compared to the last year’s volume of 1.4 million, its volume of 0.88 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 43.24%. Additionally, its Average True Range was 0.22.
During the past 100 days, Amneal Pharmaceuticals Inc’s (AMRX) raw stochastic average was set at 73.68%, which indicates a significant increase from 15.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 20.71% in the past 14 days, which was lower than the 34.15% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.53, while its 200-day Moving Average is $6.94. Nevertheless, the first resistance level for the watch stands at $8.37 in the near term. At $8.48, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.55. If the price goes on to break the first support level at $8.18, it is likely to go to the next support level at $8.11. Now, if the price goes above the second support level, the third support stands at $8.00.
Amneal Pharmaceuticals Inc (NASDAQ: AMRX) Key Stats
There are 309,543K outstanding shares of the company, which has a market capitalization of 2.55 billion. As of now, sales total 2,394 M while income totals -83,990 K. Its latest quarter income was 701,780 K while its last quarter net income were 5,990 K.
